Session 5: Safety of CRISPR/Cas9
Session 5: Safety of CRISPR/Cas9
03/06/2026 17:00
Speakers: Ayal Hendel, Toni Cathomen
Target:
Patients
Subnetworks: Red blood cell defects
Disease Groups: Sickle cell disease and related diseases
Ayal Hendel
Prof. Ayal Hendel is the principal investigator of the research Genome Editing & Gene Therapy: Presice and efficient CRISPR genome editing as a curative therapy for genetic disorders from Hendel Lab.
Toni Cathomen
- 1998-2002 Postdoctoral Fellow, Laboratory of Genetics, The Salk Institute, La Jolla, USA
- 2002-2003 Senior Research Associate, The Salk Institute, La Jolla, USA
- 2003-2009 Assistant Professor of Molecular Virology, Charité Medical School, Berlin, Germany
- 2009-2012 Associate Professor of Experimental Hematology, Hannover Medical School, Germany
- Since 2012 Full Professor (W3) and Director of the Institute for Cell and Gene Therapy, Medical Center - University of Freiburg
Focus of research
- To improve TALEN and CRISPR-Cas platforms for therapeutic applications in human stem cells
- To develop disease models and cell therapies based on induced pluripotent stem cells (iPSCs)
- To translate into the clinic cell and gene therapies for patients suffering from primary immunodeficiencies, HIV infection or leukemia